Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P14780
UPID:
MMP9_HUMAN
Alternative names:
92 kDa gelatinase; 92 kDa type IV collagenase; Gelatinase B
Alternative UPACC:
P14780; B2R7V9; Q3LR70; Q8N725; Q9H4Z1; Q9UCJ9; Q9UCL1; Q9UDK2
Background:
Matrix metalloproteinase-9 (MMP-9), also known as 92 kDa gelatinase, 92 kDa type IV collagenase, or Gelatinase B, is pivotal in the degradation of the extracellular matrix. This enzyme is capable of cleaving components such as type IV and V collagen, fibronectin, and generates the secreted form of ninjurin-1. MMP-9's activity is crucial for processes like leukocyte migration and potentially in bone osteoclastic resorption.
Therapeutic significance:
MMP-9 is implicated in diseases such as Intervertebral disc disease, characterized by degeneration of lumbar spine disks, and Metaphyseal anadysplasia 2, a bone development disorder. Understanding the role of MMP-9 could open doors to potential therapeutic strategies for these conditions.